- Home
- CRT vs BTAI Comparison
CRT vs BTAI Comparison
Compare CRT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | BTAI |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 49.2M |
| IPO Year | 1992 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CRT | BTAI |
|---|---|---|
| Price | $8.61 | $2.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 37.0K | ★ 661.6K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $5,621,913.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $416.40 |
| P/E Ratio | $11.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.07 | $1.17 |
| 52 Week High | $13.31 | $9.26 |
Technical Indicators
Market Signals| Indicator | CRT | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.23 | 51.76 |
| Support Level | $8.29 | $1.82 |
| Resistance Level | $8.99 | $2.33 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 41.82 | 62.87 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.